Business
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth -- ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced the introduction of its FemSperm Setup Kit, the first in a planned family of products designed to fully enable
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth --","length":156,"tagName":"p"},{"type":"text","content":"ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced the introduction of its FemSperm Setup Kit, the first in a planned family of products designed to fully enable gynecologists for FemaSeed Intratubal Insemination. The setup kit includes customized components, such as a pre-configured centrifuge to optimize sperm preparation for use with FemaSeed. By providing a streamlined, in-office solution, Femasys is establishing the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, expanding patient access to alternatives ahead of IVF and advancing the Company’s commercialization strategy.","length":808,"tagName":"p"},{"type":"text","content":"“Our FemSperm Setup Kit represents the beginning of a broader family of products designed to fully activate gynecologists to adopt and expand FemaSeed use,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “This strategic step strengthens our commercialization pathway by bringing FemaSeed into the hands of the physicians who see patients first, opening new access points for women seeking fertility care and positioning Femasys for scalable revenue growth.”","length":486,"tagName":"p"},{"type":"text","content":""With decades of experience in reproductive medicine and as an investigator in the completed FemaSeed trial, I performed the procedure firsthand and know it is ideally suited for gynecologists to perform," said Dr. James Liu, ...